Metabolic abnormalities in patients with prolactinoma: response to treatment with cabergoline
| Autor: | Nazir Ahmad Pala, Raiz Ahmad Misgar, Rayees Ahmad Dar, Bashir Ahmad Laway |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
medicine.medical_specialty
Waist Cabergoline business.industry Endocrinology Diabetes and Metabolism Research Insulin resistance medicine.disease Metabolic syndrome Lipids Prolactin Hyperprolactinemia Endocrinology Internal medicine Diabetes mellitus medicine Internal Medicine business Body mass index Prolactinoma medicine.drug |
| Zdroj: | Diabetology & Metabolic Syndrome |
| ISSN: | 1758-5996 |
| Popis: | Background Hyperprolactinemia has been associated with changes in body composition and metabolic abnormalities. Normalization of prolactin (PRL) with dopamine agonists has been found to reverse these abnormalities. This study was designed to assess the anthropometric and metabolic alterations associated with prolactinoma and response of these abnormalities to cabergoline treatment. Methods In a non-randomised matched prospective design, 19 consecutive patients with prolactinoma (median PRL 118.6 (105.3) μg/L) and 20 controls were studied. The controls were age, gender and body mass index (BMI) matched. Anthropometric data and metabolic variables were studied at baseline, 3 and 6 months after cabergoline treatment. Results Patients with prolactinoma had increased level of fasting plasma glucose (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|